Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Edward Carr Biography and Net Worth

CAO of Abeona Therapeutics

Ed Carr, Chief Accounting Officer, joined Abeona in 2018, bringing more than 25 years of corporate public accounting experience to the Company. Most recently, he served as Vice President and Assistant Controller at Coty Inc., a publicly listed multinational company. Mr. Carr has significant experience managing various accounting, financial reporting, internal controls, tax and treasury matters. Prior to Coty, he served for more than 10 years as Chief Accounting Officer at Foster Wheeler AG. Mr. Carr, who is a Certified Public Accountant, began his career at Ernst & Young LLP. He holds a B.S. and Master of Professional Accountancy from West Virginia University.

What is Edward Carr's net worth?: The estimated net worth of Edward Carr is at least $1.29 million as of April 5th, 2021. Mr. Carr owns 226,291 shares of Abeona Therapeutics stock worth more than $1,289,859 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. Carr may own. Learn More about Edward Carr's net worth.
How do I contact Edward Carr?: The corporate mailing address for Mr. Carr and other Abeona Therapeutics executives is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. Abeona Therapeutics can also be reached via phone at 214-665-9495 and via email at [email protected]. Learn More on Edward Carr's contact information.
Has Edward Carr been buying or selling shares of Abeona Therapeutics?: Edward Carr has not been actively trading shares of Abeona Therapeutics in the last ninety days. Most recently, Edward Carr sold 29,122 shares of the business's stock in a transaction on Friday, October 8th. The shares were sold at an average price of $1.05, for a transaction totalling $30,578.10. Learn More on Edward Carr's trading history.
Who are Abeona Therapeutics' active insiders?: Abeona Therapeutics' insider roster includes Michael Amoroso (CEO), Edward Carr (CAO), Brendan O'Malley (SVP), and Todd Wider (Director). Learn More on Abeona Therapeutics' active insiders.
Are insiders buying or selling shares of Abeona Therapeutics?: During the last twelve months, Abeona Therapeutics insiders bought shares 5 times. They purchased a total of 42,758 shares worth more than $154,047.12. During the last twelve months, insiders at the biopharmaceutical company sold shares 1 times. They sold a total of 7,084 shares worth more than $36,199.24. The most recent insider tranaction occured on May, 16th when Director Leila Alland bought 11,000 shares worth more than $51,810.00. Insiders at Abeona Therapeutics own 5.4% of the company. Learn More about insider trades at Abeona Therapeutics.
Information on this page was last updated on 5/16/2024.

Edward Carr Insider Trading History at Abeona Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/8/2021	Sell	29,122	$1.05	$30,578.10
4/5/2021	Sell	35,000	$1.80	$63,000.00	226,291
4/1/2021	Sell	20,445	$1.85	$37,823.25	226,291

Edward Carr Buying and Selling Activity at Abeona Therapeutics

Abeona Therapeutics Company Overview

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Today's Range

Now: $5.70

$5.56

$5.79

50 Day Range

MA: $6.16

$5.63

$6.74

2 Week Range

Now: $5.70

$3.05

$9.01

Volume

210,374 shs

Average Volume

415,259 shs

Market Capitalization

$247.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44